EPISODE · Mar 6, 2026 · 1 MIN
ACT Brief: Bayesian Methods Drive Adaptive Trials, Digital Endpoints Gain Regulatory Footing, and FDA Cracks Down on Compounded GLP-1 Marketing
from Applied Clinical Trials · host Applied Clinical Trials
In today's ACT Brief, we explore how Bayesian approaches are powering studies in rare disease and pediatrics, a major public-private initiative is standardizing digital endpoints for regulatory acceptance, and the FDA intensifies enforcement against misleading GLP-1 marketing.
Embed this episode
Ready to play
ACT Brief: Bayesian Methods Drive Adaptive Trials, Digital Endpoints Gain Regulatory Footing, and FDA Cracks Down on Compounded GLP-1 Marketing
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.